GlycoMimetics Shares Are Soaring Tuesday: Here's Why
GlycoMimetics Shares Are Soaring Tuesday: Here's Why
The merger transaction is anticipated to close in the second quarter of 2025, with the financing transaction expected to close immediately afterward.GlycoMimetics, Inc. (NASDAQ:GLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent Biopharma. The company also said it secured $200 million in funding to advance its oncology pipeline.
納斯達克上的glycomimetics公司（NASDAQ:GLYC）股價週二上漲，原因是公司宣佈將與Crescent Biopharma合併。該公司還表示已獲得20000萬美元的資金，用於推進其腫瘤學產品線。
What To Know: GlycoMimetics has entered into an acquisition agreement with privately held biotech firm Crescent BioPharma. The combined company, which will operate under the name Crescent Biopharma, Inc., will focus on advancing Crescent Biopharma's current solid tumor portfolio, including its lead therapies CR-001, CR-002 and CR-003.
關鍵信息：GlycoMimetics已與私人生物科技公司Crescent BioPharma達成收購協議。合併後的公司將以Crescent Biopharma, Inc.的名義運營，重點發展Crescent Biopharma目前的實體腫瘤產品組合，包括其主要療法CR-001、CR-002和CR-003。
In support of the merger, a group of investors has agreed to purchase $200 million in the combined company's common stock and pre-funded warrants. The purpose of the funding is to support operations through 2027, including further developing lead therapeutic treatments.
支持該併購的一組投資者已同意購買合併後公司的普通股和預先融資認股權，金額爲20000萬美元。這筆資金的目的是支持到2027年的運營，包括進一步開發主要治療方法。
The merger transaction is anticipated to close in the second quarter of 2025, with the financing transaction expected to close immediately afterward.
預計併購交易將在2025年第二季度完成，融資交易預計隨後立即完成。
Under the acquisition agreement, pre-acquisition GlycoMimetics stockholders will hold about 3.1% of the combined company, while pre-acquisition Crescent stockholders, including those involved in pre-closing financing, will own roughly 96.9%.
根據收購協議，收購前的GlycoMimetics股東將持有合併後公司約3.1%的股份，而包括參與封閉前融資的收購前Crescent股東將擁有約96.9%的股權。
"We are confident that our transaction with Crescent represents a significant opportunity for GlycoMimetics and its stockholders," said Harout Semerjian, CEO of GlycoMimetics.
"我們相信與Crescent的交易對於GlycoMimetics及其股東來說是一個重要機會，"GlycoMimetics的CEO Harout Semerjian表示。
"This transaction is the result of a comprehensive strategic review, and with additional funding for Crescent's portfolio of novel biologics, we believe the company is well-positioned to carry forward the mission of seeking to improve the lives of patients."
"此次交易是一個全面戰略審查的結果，加上對Crescent的新型生物製品組合的額外資金支持，我們相信公司有很好的機會繼續推進改善患者生活的使命。"
GlycoMimetics stock is trading on above-average volume Tuesday. The company's average session volume over the past 100 days is 1.05 million, but Tuesday's trading volume was around 856 million at the time of publication.
週二，GlycoMimetics股票的交易量高於平均水平。公司過去100天的平均交易量爲105萬，但在本次發佈時，週二的交易量約爲85600萬。
Related Link: What's Going On With Boeing Stock Monday?
相關鏈接：波音股票週一發生了什麼？
GLYC Price Action: At the time of publication, GlycoMimetics shares are up 210.1% at 52 cents, according to data from Benzinga Pro.
GLYC股價表現：根據Benzinga Pro的數據，在發佈時，glycomimetics股票上漲210.1%，報價爲52美分。
Image: Image: Akava Photo from Pixabay
圖片: 圖片: 來自Pixabay的Akava照片
譯文內容由第三人軟體翻譯。
